Back to top
more

Veracyte (VCYT)

(Delayed Data from NSDQ)

$34.83 USD

34.83
1,467,292

-0.42 (-1.19%)

Updated Sep 20, 2024 03:59 PM ET

After-Market: $34.87 +0.04 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte

by Zacks Equity Research

Intuitive Surgical, Masimo and Veracyte have been highlighted in this Industry Outlook article

Urmimala Biswas headshot

3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost

by Urmimala Biswas

ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

by Zacks Equity Research

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Should You Continue to Retain ABT Stock in Your Portfolio Now?

by Zacks Equity Research

Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

Here's Why Veracyte (VCYT) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Should You Consider Retaining ZBH Stock in Your Portfolio Now?

by Zacks Equity Research

Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.

Should You Continue to Retain PODD Stock in Your Portfolio Now?

by Zacks Equity Research

Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.

Should You Consider Retaining Bruker Stock in Your Portfolio Now?

by Zacks Equity Research

BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.

Nilanjan Choudhury headshot

5 Relative Price Strength Stocks That You Should Buy Now

by Nilanjan Choudhury

SNCR, MCY, UHS, VCYT and MWA are five stocks with explosive relative price strength.

Is It Apt to Hold Globus Medical Stock in Your Portfolio Now?

by Zacks Equity Research

GMED's robust prospects in the musculoskeletal field and the synergies from the NuVasive merger bode well. Yet, macroeconomic issues can affect performance.

Should You Hold Labcorp (LH) Stock in Your Portfolio Now?

by Zacks Equity Research

Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.

Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y

by Zacks Equity Research

Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.

Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Veracyte, Inc. (VCYT) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up

by Zacks Equity Research

Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.

Veracyte (VCYT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veracyte (VCYT) delivered earnings and revenue surprises of 1,100% and 14.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical (GMED) Global Sales, Innovation Aid Growth

by Zacks Equity Research

In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.

Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D

by Zacks Equity Research

Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.

Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?

by Zacks Equity Research

Veracyte (VCYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: NVIDIA, Twist Bioscience, Ollie's Bargain Outlet in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.